STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Medpace (MEDP) Form 144: 10,000-share sale via Fidelity valued at $4.8M

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Medpace Holdings, Inc. (MEDP) Form 144 notice shows an intended sale of 10,000 common shares through Fidelity Brokerage Services on 09/03/2025 with an aggregate market value of $4,800,019.30. The shares were acquired by the seller via a stock option exercise on 08/05/2024 and paid in cash. The filing reports 28,093,026 shares outstanding. The same person sold 7,500 shares on 07/28/2025 for gross proceeds of $3,376,083.14. The filer attests there is no undisclosed material adverse information and includes the required sale and acquisition details.

Positive

  • Transparent sourcing: Shares were acquired by a stock option exercise on 08/05/2024 and paid in cash, clearly disclosed
  • Complete sale details: Broker, number of shares, aggregate market value, and approximate sale date are provided
  • Attestation included: Seller represents no undisclosed material adverse information, satisfying a key Rule 144 requirement

Negative

  • Insider selling: Planned sale of 10,000 shares and a recent sale of 7,500 shares may be viewed negatively by some investors
  • Lack of trading-plan detail: Form does not indicate adoption date of any 10b5-1 trading plan or instruction in the provided fields

Insights

TL;DR Insider plans to sell 10,000 shares acquired by option exercise; prior sale of 7,500 shares reported recently.

This Form 144 discloses a routine insider sale executed through a broker with clear sourcing: the 10,000 shares were acquired by exercising options and paid in cash on 08/05/2024. The planned sale value of about $4.8 million is explicitly stated. Compared with the reported 28,093,026 shares outstanding, the 10,000-share sale represents a very small fraction of the float, indicating limited direct dilution or market impact from this single notice. Recent sale activity of 7,500 shares on 07/28/2025 for roughly $3.38 million shows continued disposition of shares by the same person within the reporting window. Overall this appears procedural and compliant with Rule 144 disclosure norms.

TL;DR Filing documents insider exercise and subsequent sales; disclosure language affirms no undisclosed material information.

The notice includes the required attestation that the seller is not aware of undisclosed material adverse information. The acquisition method (stock option exercise) and cash payment are clearly documented, which supports transparent governance practices around insider transactions. The filing does not include any indication of a trading plan date or 10b5-1 instruction; that absence is explicitly observable in the form fields presented. From a governance perspective, the form meets Rule 144 content requirements but provides no additional context about the seller's rationale or any pre-existing trading plan.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the MEDP Form 144 disclose about the planned sale?

The filing discloses an intended sale of 10,000 common shares via Fidelity on 09/03/2025 with an aggregate market value of $4,800,019.30.

How were the 10,000 shares acquired according to the filing?

The shares were acquired by a stock option exercise on 08/05/2024 and paid for in cash on that date.

Has the person sold any MEDP shares recently?

Yes. The filing reports a sale of 7,500 shares on 07/28/2025 for gross proceeds of $3,376,083.14.

How large is the planned sale relative to outstanding shares?

The filing lists 28,093,026 shares outstanding; the planned sale of 10,000 shares is a small fraction of that total.

Does the Form 144 state there is undisclosed material information?

No. By signing the notice the seller represents they do not know any material adverse information that is not publicly disclosed.
Medpace Holdings

NASDAQ:MEDP

MEDP Rankings

MEDP Latest News

MEDP Latest SEC Filings

MEDP Stock Data

16.56B
22.65M
20.7%
96.78%
8.02%
Diagnostics & Research
Services-commercial Physical & Biological Research
Link
United States
CINCINNATI